Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2610]

FDA approves use of pemetrexed for non-small cell lung cancer

FDA approves use of pemetrexed for non-small cell lung cancer

Skin rash predicts survival benefit from latest lung cancer drug

Skin rash predicts survival benefit from latest lung cancer drug

Smoking in cars produces harmful pollutants at levels above WHO indoor air quality standards

Smoking in cars produces harmful pollutants at levels above WHO indoor air quality standards

FDA approves injectable paclitaxel protein-bound particles in combination with carboplatin for NSCLC

FDA approves injectable paclitaxel protein-bound particles in combination with carboplatin for NSCLC

Scottish cigarette vending appeal rejected

Scottish cigarette vending appeal rejected

Novel blood-based protein signature determined for rare, aggressive lung cancer

Novel blood-based protein signature determined for rare, aggressive lung cancer

ESMO 2012: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

ESMO 2012: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

ESMO 2012: New weapons in the fight against cancer

ESMO 2012: New weapons in the fight against cancer

ESMO 2012: Myths and misunderstandings hamper efforts to prevent cancer

ESMO 2012: Myths and misunderstandings hamper efforts to prevent cancer

ESMO 2012: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

ESMO 2012: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III...

More from ecancer